ORIGINAL SOURCES · 07 / REFERENCES
Where can you read the BPC-157 TB-500 sources yourself?
The numbered notes open the studies themselves, the later reviews, and the FDA pages so you can check what was studied.
What you will find in each group of sources
The BPC-157 TB-500 references let you trace each claim. Sources 1-5 cover the separate peptides, including the rat tendon study and work on moving cells. Sources 6-8 review the animal and human work. Source 9 covers study amounts and the limited human background. Sources 10-12 are FDA pages behind the pharmacy facts.
Each numbered note leads to one source.
You can check every study, but you won't find proof that Wolverine works. When no fair trial of the pair exists, the source shows what researchers tested instead. The Wolverine blend references hold the full record.
Before relying on a source, ask who or what was studied, which peptide or protein was used, and whether the change measured answers your question.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
- Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. ↗
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. ↗
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. ↗
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
- Dosing-context and human-data synthesis for BPC-157 and TB-500 (constituent rodent dose ranges, the rat/dog BPC-157 elimination half-life of under 30 minutes, full-length Thymosin Beta-4 human Phase 1 pharmacokinetics, and the absence of any controlled BPC-157 + TB-500 combination trial), compiled from the studies cited at refs 1-8 and the corpus research record. ↗
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. ↗
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 entries for BPC-157 and for 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; entries effective September 29, 2023). ↗
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 / Category 2 definitions; the 503A/503B framework; the January 7, 2025 revised interim policy). ↗
- Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
- Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
- Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
- et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗